Diagnostic challenges for Pompe disease: An under-recognized cause of floppy baby syndrome

Pompe disease, a disorder caused by a deficiency in the lysosomal enzyme acid alpha glucosidase, is frequently overlooked as a cause of floppy baby syndrome. The accurate diagnosis of floppy baby syndrome requires the sequential evaluation of medical causes (e.g., hypothyroidism, sepsis, malnutrition, malabsorption, congenital heart disease), neurologic etiologies (central [cerebral] and peripheral [lower motor unit]) and anatomic characteristics of the abnormality. Cardiomegaly on chest x-ray in a patient with floppy baby syndrome should alert the pediatrician to suspect Pompe disease. Based on this finding, further work-up or referral to a specialist can be considered. Pompe disease requires immediate attention. Symptomatic intervention of this disorder should be initiated at the earliest time possible to maximize the potential benefit from therapy and to prevent irreversible organ damage. Moreover, early diagnosis is important for providing parents with realistic information about their child's prognosis, and where appropriate, professional genetic counseling. Enzyme replacement therapy (ERT) with recombinant human GAA is currently being evaluated in clinical trials; the future availability of this option makes early identification of this condition even more critical. This article presents a unified view on the optimal approach to the accurate diagnosis of Pompe disease and to its recognition as one of the possible and treatable causes of floppy baby syndrome.

[1]  A. Kahn,et al.  Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation. , 1998, Human molecular genetics.

[2]  J. Charrow,et al.  Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial , 2001, Genetics in Medicine.

[3]  A. Reuser,et al.  Enzyme therapy for Pompe disease: from science to industrial enterprise , 2007, European Journal of Pediatrics.

[4]  A. Reuser,et al.  Glycogenosis type II (acid maltase deficiency) , 1995, Muscle & nerve. Supplement.

[5]  L. Sandkuijl,et al.  Glycogen Storage Disease Type II: Birth Prevalence Agrees with Predicted Genotype Frequency , 2000, Public Health Genomics.

[6]  M. Kroos,et al.  Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling , 1999, European Journal of Human Genetics.

[7]  I. Nishino Autophagic vacuolar myopathies , 2003, Current neurology and neuroscience reports.

[8]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[9]  J. Smeitink,et al.  Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk , 2001, Journal of Inherited Metabolic Disease.

[10]  T. Choudhury,et al.  Glycogen storage disease (type-III). , 1991, Indian pediatrics.

[11]  W. Hop,et al.  Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human -Glucosidase From Milk , 2004 .

[12]  W. Rom,et al.  Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. , 1998, American journal of medical genetics.

[13]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[14]  C. Prasad,et al.  The floppy infant: contribution of genetic and metabolic disorders , 2003, Brain and Development.

[15]  A. Ross,et al.  Anaesthetic management of infants with glycogen storage disease type II: a physiological approach , 2004, Paediatric anaesthesia.

[16]  Phillip D. K. Lee Disease management of Prader–Willi syndrome , 2002, Expert opinion on pharmacotherapy.

[17]  H. Jones,et al.  Diagnosis of pediatric neuromuscular disorders in the era of DNA analysis. , 2000, Pediatric neurology.

[18]  A. Reuser,et al.  Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. , 2000, Lancet.

[19]  J. Metzl,et al.  An Interesting Case of Infant Sudden Death: Severe Hypertrophic Cardiomyopathy in Pompe's Disease , 1999, Pacing and clinical electrophysiology : PACE.

[20]  A. Vulto,et al.  Recombinant human α-glucosidase from rabbit milk in Pompe patients , 2000, The Lancet.

[21]  P. Meikle,et al.  Determination of Acid α-Glucosidase Protein: Evaluation as a Screening Marker for Pompe Disease and Other Lysosomal Storage Disorders , 2000 .

[22]  A. Haqq,et al.  Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  M. Gelb,et al.  Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. , 2004, Clinical chemistry.

[24]  C. Berul Electrophysiological phenotyping in genetically engineered mice. , 2003, Physiological genomics.

[25]  R. Howell,et al.  Pompe disease in infants and children. , 2004, The Journal of pediatrics.

[26]  L. Severijnen,et al.  Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy , 2003, Muscle & nerve.

[27]  J. Smeitink,et al.  Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. , 2001, Journal of inherited metabolic disease.

[28]  D. Allen,et al.  Prader-Willi syndrome: how does growth hormone affect body composition and physical function? , 2001, Journal of Pediatric Endocrinology & Metabolism (JPEM).

[29]  B. Byrne,et al.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). , 2002, Current molecular medicine.

[30]  M. Shevell,et al.  Diagnostic profile of neonatal hypotonia: an 11-year study. , 2001, Pediatric neurology.